SCHEMBL25835445

SCHEMBL25835445

CC(C)(C)OC(=O)NCCOCCC(=O)NCCOCCNC(=O)CCCCCCCCCCCCCCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.53
CYP3A4 P08684 1/20 0.53
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
IDO1 P14902 1/20 0.50
HDAC1 Q13547 3/20 0.49
HDAC2 Q92769 3/20 0.49
HDAC3 O15379 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
NCOR2 Q9Y618 2/20 0.49
HDAC4 P56524 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
LMNA P02545 3/20 0.49
TSHR P16473 1/20 0.49
F13A1 P00488 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25772085 0.92 SIGMAR1 (0.56) SIGMAR1CYP3A4CA1CA2IDO1
SCHEMBL4727587 0.90 SIGMAR1 (0.60) SIGMAR1CYP3A4CA1CA2HDAC1
SCHEMBL26384487 0.86 SIGMAR1 (0.61) SIGMAR1CYP3A4CA1CA2HDAC1
SCHEMBL4889499 0.85 CA1 (0.65) SIGMAR1CYP3A4CA1CA2HDAC1
SCHEMBL6274138 0.83 NPSR1 (0.56) SIGMAR1CYP3A4CA1CA2IDO1
SCHEMBL24383295 0.83 LMNA (0.63) SIGMAR1CYP3A4CA1CA2IDO1
SCHEMBL25835446 0.82 HDAC1 (0.54) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL29994442 0.82 LMNA (0.51) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL5468072 0.82 NPSR1 (0.61) SIGMAR1CYP3A4IDO1LMNATSHR
SCHEMBL22102023 0.82 NPSR1 (0.61) SIGMAR1CYP3A4IDO1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 SIGMAR1 4191/4885CYP3A4 4669/4885CA1 4853/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 SIGMAR1 2756/4885CYP3A4 4588/4885CA1 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.